<DOC>
	<DOCNO>NCT02065973</DOCNO>
	<brief_summary>Phase I , open-label , sequential-cohort , ascend multiple-dose study evaluate safety tolerability escalate dos PDS0101 female subject high-risk HPV infection biopsy-proven CIN1 . The study include 3 cohort 3 6 subject base modify `` 3 + 3 '' dose-escalation study design . The study initiate Cohort 1 progress Cohort 3 , subsequent cohort receive high dose PDS0101 . Successive cohort receive constant dose HPV-16 E6 E7 peptide . All subject receive 3 vaccination SC give approximately 21 day apart . Dosing dose escalation base safety evaluation determination potential dose-limiting toxicity ( DLT ) .</brief_summary>
	<brief_title>An Open-Label , Phase I , Escalating Dose Study Evaluate Safety , Tolerability , Pharmacodynamics PDS0101</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<criteria>1 . Written inform consent prior initiation studyrelated procedure ; 2 . Nonlactating female age 21 65 year , inclusive ; 3 . Nonchildbearing potential ( define surgically sterile least 2 year postmenopausal ) practice effective contraception ( defined 2 concurrent method contraception , 1 barrier method ) agree continue use effective contraception throughout duration study ; 4 . Not pregnant base negative result serum human chorionic gonadotropin ( HCG ) test screen Visit 1 negative urine pregnancy test prevaccination Visit 2 ( subsequent vaccination visit ) ; 5 . Pap test document atypical squamous cell undetermined significance ( ASCUS ) /HPV+ , atypical squamous cell high grade ( ASCH ) , lowgrade squamous intraepithelial lesion ( LSIL ) , highgrade squamous intraepithelial lesion ( HSIL ) within 4 month prior screen Visit 1 ; 6 . History pathologically confirm CIN1 colposcopicallydirected punch biopsy , within 12 week prior administration first study vaccination ( CIN 2/3 subject eligible ) ; 7 . For diagnosis CIN1 , document satisfactory colposcopy , ie , entire lesion well entire squamocolumnar junction visualizible colposcopy ; 8 . Confirmed highrisk HPV infection commercially available highrisk DNA assay ( eg , Hybrid Capture II [ Qiagen ] ) ; 9 . Good health adequate hematologic , renal , hepatic , cardiac function , determine Investigator , base upon medical history , physical examination , laboratory test result screen visit ( Visit 1 ) : Bone marrow function : absolute neutrophil count ≥1,500/µL , platelets ≥ 100,000/ µL ; Renal function : creatinine ≤ 1.5 x institutional upper limit normal ( ULN ) ; Hepatic function : total bilirubin ≤ 1.5 x ULN ( Common Terminology Criteria AEs [ CTCAE ] v4.0 grade 1 ) except patient Gilbert 's disease ( 5.0 mg/dL ) . Aspartate aminotransferase ( AST ) alkaline phosphatase ≤ 2.5 x ULN . Normal Cardiac function : assessed history physical exam . 1 . Atypical endometrial glandular cell evidence invasive cervical carcinoma cervical biopsy ; 2 . Previous history cancer , adequately treat basal cell Stage 1 squamous cell carcinoma skin ; 3 . Current recognize immunodeficiency disease , include infection HIV , cellular immunodeficiency , hypogammaglobulinemia , dysgammaglobulinemia , hereditary congenital immunodeficiency . 4 . Received immunotherapy ( eg , IFNs , tumor necrosis factor , interleukin , biological response modifier [ granulocytemacrophage colonystimulating factor , granulocyte colonystimulating factor , macrophage colonystimulating factor ] ) within 30 day prior administration first study vaccination ; 5 . Serious , concomitant disorder , include active systemic infection require treatment , opinion investigator ; 6 . Currently receive receive treatment systemic steroid follow dosage within 30 day prior administration first study vaccination . Chronic longterm corticosteroid : ≥0.5 mg/kg/day oral prednisolone equivalent Sporadic corticosteroid : ≥1 mg/kg/day oral prednisolone equivalent 2 short course &gt; 3 day Note : Current recent use intraarticular , topical inhale glucocorticoid therapy acceptable ; 7 . Other condition prior therapy , opinion Investigator , compromise subject 's welfare may confound study result ; 8 . Participation another investigational study concurrently use another investigational drug within 6 month prior administration first study vaccination ; 9 . Previously enrol study .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>